Real World Efficacy and Safety Results of Ixazomib Lenalidomide and Dexamethasone Combination in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Ixazomib Named Patient Program

[1]  P. Richardson,et al.  Healthcare resource utilization with ixazomib or placebo plus lenalidomide-dexamethasone in the randomized, double-blind, phase 3 TOURMALINE-MM1 study in relapsed/refractory multiple myeloma , 2018, Journal of medical economics.

[2]  C. Cleeland,et al.  Patient‐reported health‐related quality of life from the phase III TOURMALINE‐MM1 study of ixazomib‐lenalidomide‐dexamethasone versus placebo‐lenalidomide‐dexamethasone in relapsed/refractory multiple myeloma , 2018, American journal of hematology.

[3]  E. Cummins,et al.  Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology Appraisal , 2018, PharmacoEconomics.

[4]  M. Dimopoulos,et al.  A Comparison of the Efficacy of Immunomodulatory‐containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta‐analysis , 2018, Clinical lymphoma, myeloma & leukemia.

[5]  D. Esseltine,et al.  Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. , 2017, Blood.

[6]  M. Dimopoulos,et al.  "Real World" Data on the Efficacy and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Combined Study from the Greek, Czech and UK Databases , 2017 .

[7]  P. Richardson,et al.  Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1 , 2017, Haematologica.

[8]  Zaina T. Al-Salama,et al.  Ixazomib: A Review in Relapsed and/or Refractory Multiple Myeloma , 2017, Targeted Oncology.

[9]  A. Mehta,et al.  REAL WORLD USE OF IXAZOMIB WITH LENALIDOMIDE AND DEXAMETHASONE FOR PATIENTS WITH RELAPSED AND RELAPSED REFRACTORY MULTIPLE MYELOMA , 2017 .

[10]  A. Palumbo,et al.  Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. , 2016, The New England journal of medicine.

[11]  B. Barlogie,et al.  International uniform response criteria for multiple myeloma , 2006, Leukemia.